Clinical trials: Opinions
Cancer
Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
The purpose of this Expanded Access Program (EAP) is to allow patients to continue receiving treatment with copanlisib if they are currently having, in the opinion of their healthcare provider, an objective favorable response…
- Trial name
- NCT06238583
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 11 sites in Brazil, Chile and 9 more
- Sponsor
- Bayer